Ipsen SA (STU:I7G)
€ 120.3 1 (0.84%) Market Cap: 10.07 Bil Enterprise Value: 9.85 Bil PE Ratio: 15.60 PB Ratio: 2.61 GF Score: 92/100

Ipsen SA to Discuss the ELATIVE Phase III Trial Results Call Transcript

Nov 14, 2023 / 03:30PM GMT
Release Date Price: €105 (+0.10%)
Operator

Hello, and welcome to Ipsen's Investor Science call at AASLD. I'd now like to turn over to Craig Marks of Ipsen.

Craig Marks
Ipsen S.A. - Vice-President of IR

Hello, everyone. As you just heard, I'm Craig Marks, Vice President of Investor Relations at Ipsen. We're live in Boston, and it's a real pleasure to welcome you at Ipsen's Investor Science Conference Call here at the 2023 AASLD meeting. The plan for this call is to focus on the results from the elafibranor ELATIVE Phase III trial presented yesterday at the late-breaker session.

We plan to comment today only on the results of the trial. Commercial questions will be answered at next month's Capital Markets Day.

Next slide, please. This is our usual safe harbor statement. Next slide, please. I'd now like to introduce you to our 3 speakers today. Jennifer Schranz, Global Head of Rare Disease R&D, Ipsen will summarize our focus in rare disease and our extensive presence at AASLD over the past few days. Dr. Christopher Bowlus, Professor and Chief of the Division of Gastroenterology and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot